ClearView 3 IOL
Lenstec, Inc. · Decision date Mar 25, 2026
What did the FDA approve?
FDA records P200020/S011 as a supplement to PMA P200020, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Mar 25, 2026.
FDA approval order statement
approval for an extension of the power range from +15.0 through +30.0D to +10.0 through +36.0D for the ClearView 3 intraocular lenses (IOLs)
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Ophthalmic
- Decision date
- Mar 25, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P200020/S011
- Regulatory pathway
- PMA supplement
- Applicant
- Lenstec, Inc.
- Product code
- MFK
- Decision code
- APPR
- Decision date
- Mar 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, multifocal intraocular.
- Applicant
- Lenstec, Inc.
- Product code
- MFK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200020 · Original PMA
SBL-3 Multifocal Intraocular Lens
P200020/S009 · Related supplement
ClearView 3 Lens
P200020/S010 · Related supplement
ClearView 3
P200020/S011 received
Application receipt date recorded by FDA.
P200020/S011 · FDA decision
Real-Time Process
P200020/S012 · Related supplement
Clearview 3
P200020/S013 · Related supplement
ClearView HD intraocular lens (IOL)
Timeline entries are records held by MedtechLedger for P200020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Lenstec, Inc. | PMA approval | Jul 22, 2022 | FDA | |
ClearView 3 LensP200020/S009 | Lenstec, Inc. | PMA supplement | Aug 12, 2025 | FDA |
ClearView 3P200020/S010 | Lenstec, Inc. | PMA supplement | Dec 4, 2025 | FDA |
Clearview 3P200020/S012 | Lenstec, Inc. | PMA supplement | Apr 15, 2026 | FDA |
ClearView HD intraocular lens (IOL)P200020/S013 | Lenstec, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code MFK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
TECNIS Multi-focal 3-pc, Model ZMA00P080010/S032 | Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
| Bausch + Lomb, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
| Bausch + Lomb, Inc. | PMA supplement | Sep 30, 2026 | FDA | |
| Rayner Intraocular Lenses , Ltd. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lenstec, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1765 Commerce Ave. N, St. Petersburg, FL, 33716
Sources and methodology
- Original FDA record: P200020/S011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




